ProfileGDS5678 / 1415925_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 67% 73% 73% 74% 73% 70% 63% 73% 73% 73% 76% 74% 73% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.1288567
GSM967853U87-EV human glioblastoma xenograft - Control 24.7086373
GSM967854U87-EV human glioblastoma xenograft - Control 34.7089573
GSM967855U87-EV human glioblastoma xenograft - Control 44.9199474
GSM967856U87-EV human glioblastoma xenograft - Control 54.7545273
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.369970
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8349663
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.6822873
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.6818473
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.7061873
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.0252576
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.8202174
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.7123973
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.8772175